Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 04/25 04:42:48 pm
65.09 EUR   -0.60%
04/04UCB : Transparency notification The Capital Group Companies Inc
AQ
04/04UCB : Acquisition of own shares
AQ
03/23UCB : Convening notice to attend the general meeting of shareholders..
GL
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about UCB
04/04UCB : Transparency notification The Capital Group Companies Inc
AQ
04/04UCB : Acquisition of own shares
AQ
03/23UCB : Convening notice to attend the general meeting of shareholders to be held ..
GL
03/23UCB : Extraordinary general shareholder meeting
CO
02/21Arix, Fosun in China-focused deal
AQ
02/16UCB : Advances Psoriasis Pipeline with Positive Data at American Academy &hellip..
PU
01/31UCB : Transparency Notification
AQ
01/29UCB : Transparency Notification
PU
01/12Pfizer's Barrett named CEO of Novartis Oncology
AQ
01/11AMGEN : European Medicines Agency Accepts Filing for EVENITY
AQ
01/09UCB : European Medicines Agency Accepts Filing for EVENITYTM
AQ
2017European stocks sink on Flynn guilty plea after choppy session
RE
2017European stocks sink on Flynn guilty plea after choppy session
RE
2017UCB : New study data shows prior osteoporotic fractures put women at increased r..
AQ
2017DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
AQ
More most relevant news
All news about UCB
04/05UCB : Patent Issued for Treatment for Bone Diseases (USPTO 9925260)
AQ
04/04UCB : Transparency notification The Capital Group Companies Inc
AQ
04/04UCB : Acquisition of own shares
AQ
03/23UCB : Convening notice to attend the general meeting of shareholders to be held ..
GL
03/23UCB : Extraordinary general shareholder meeting
CO
03/15UCB : Data on Cardiology Detailed by Researchers at UCB S.A. (miR-21-5p as a pot..
AQ
03/08UCB : Patent Issued for Systems and Methods for Administering Medication (USPTO ..
AQ
02/21Arix, Fosun in China-focused deal
AQ
02/16UCB : Advances Psoriasis Pipeline with Positive Data at American Academy &hellip..
PU
02/08UCB : New Findings on Biomarkers Described by Investigators at UCB S.A. (Dampeni..
AQ
More news
Sector news : Pharmaceuticals - NEC
03:56pINVESCO UK LTD INVESCO LTD. : Form 8.3 - Shire Plc
DJ
03:18pGLAXOSMITHKLINE : 1Q Earnings Impacted by FX Effects -- Earnings Review
DJ
03:11pCurrency and pricing squeeze GSK as new shingles vaccine shines
RE
02:46pShire willing to back $64 billion Takeda bid, market signals doubts
RE
02:16pShire willing to back $64 billion Takeda bid, market signals doubts
RE
01:50pGLAXOSMITHKLINE : 1Q Profit and Revenue Falls, Backs Guidance
DJ
More sector news : Pharmaceuticals - NEC
Official Publications
03/23Extraordinary general shareholder meeting 
02/22Annual results 
2017Annual Report 
20173rd quarter earnings 
2017Threshold crossings 
20171st quarter results 
More official Publications
News from SeekingAlpha
02/23UCB S.A. 2017 Q4 - Results - Earnings Call Slides 
02/22UCB S.A. reports FY results 
01/20YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O.. 
01/19Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket 
01/08EMA accepts UCB's marketing application for osteoporosis med romosozumab 
2017Dermira to returns rights to psoriasis candidate Cimzia back to UCB; shares d.. 
Latest Tweets
04/20Belgium-based UCB says it expects to submit an NDA to U.S. regulators before ..
3
04/20UCB offers $370M for Proximagen’s epilepsy spray, with NDA to follow  
04/20UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasa.. 
04/20UCB snags an NDA-ready epilepsy drug from Proximagen in $370M deal
3
04/20UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasa.. 
More tweets
Qtime:41
Financials (€)
Sales 2018 4 545 M
EBIT 2018 1 104 M
Net income 2018 757 M
Finance 2018 110 M
Yield 2018 1,90%
P/E ratio 2018 16,30
P/E ratio 2019 14,37
EV / Sales 2018 2,80x
EV / Sales 2019 2,58x
Capitalization 12 814 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 69,2 €
Spread / Average Target 5,6%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-1.06%15 652
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.13%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398